Emcure Pharmaceuticals Limited
Incorporated in 1981, Emcure Pharmaceuticals Limited is an Indian company that develops, manufactures, and markets a wide range of pharmaceutical products globally across several major therapeutic areas.
What Emcure files
- Others61
- Investor Meet33
- Updates23
- Important22
- Board Meeting10
- JV/Acquisition9
Emcure Pharmaceuticals announced its 45th Annual General Meeting (AGM) via video conference. The Annual Report for FY 2025-26 is available online. Shareholders with physical shares need to update KYC; also, submit documents for TDS exemption on the final dividend.
Emcure Pharmaceuticals received the USFDA's Establishment Inspection Report (EIR) for its Sanand facility. The inspection is closed with a 'Voluntary Action Indicated' (VAI) classification, signaling a positive regulatory outcome for the plant and no action required by the FDA.
Emcure's Poviztra® (semaglutide) received CDSCO approval for MASH treatment, expanding its market into a significant unmet medical need. This makes it the first GLP-1 receptor agonist approved for this progressive liver disease in India, bolstering Emcure's metabolic portfolio.
Emcure fully acquired Gennova by buying the remaining 12.05% minority stake, making it a wholly-owned subsidiary. This sharpens its focus on biologics and biosimilars, with Samit Mehta now leading Gennova. The company expects no material financial impact from this consolidation.
Emcure's Sanand facility received a US FDA Form 483 with 7 procedural observations following an inspection. The company is addressing these findings and plans to respond to the FDA promptly, highlighting ongoing operational compliance efforts.